China’s Suzhou GenAssist Therapeutics Co., Ltd, a base editing technology-based gene therapy developer, reportedly raised “tens of millions” of US dollars in a Series A financing round. The medical business jointly set up by AstraZeneca and CICC Capital led the round, which included contributions from Baidu Venture, Sequoia Capital China, and some reputable equity investment institutions. Proceeds will go towards pre-clinical studies, IND filings, and clinical studies for multiple pipelines.
Company Background and Technology
Founded in 2020, GenAssist develops gene therapies based on the TAM (Targeted AID-based Mutagenesis) base editing technology, with the first product indicated for the treatment of Duchenne muscular dystrophy (DMD).-Fineline Info & Tech
